LPOXY Therapeutics is acquiring selected assets from Xeno Biosciences to enhance its clinical capabilities in infectious disease prevention.
Information on the Target
LPOXY Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing cutting-edge therapies aimed at preventing infectious diseases. The company is at the forefront of research, focusing on innovative approaches to enhance patient outcomes by targeting infectious agents more effectively.
Recently, LPOXY announced a strategic move to expand its portfolio by signing a term sheet to acquire selected assets from Xeno Biosciences Inc. This acquisition includes critical regulatory filings, correspondence with various global regulatory bodies, and comprehensive Chemistry, Manufacturing, and Controls (CMC) data, which are essential for the advancement of drug development.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The biopharmaceutical industry in the United States has been experiencing rapid growth, driven by an increasing demand for innovative therapies and the ongoing advancements in biotechnolog
Similar Deals
CitiusTech Inc. → Health Data Movers Inc.
2025
Eli Lilly and Company → SiteOne Therapeutics, Inc.
2025
CCC Intelligent Solutions → EvolutionIQ
2025
LPOXY Therapeutics, Inc.
invested in
Xeno Biosciences Inc.
in 2025
in a Other deal
Disclosed details
Transaction Size: $8M